Journal article
Early Mixed Donor Chimerism is a Strong Negative Prognostic Indicator in Allogeneic Stem Cell Transplant for AML and MDS
Abstract
BACKGROUND: Allogeneic bone marrow transplantation remains the most potent curative therapy for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) due to the graft-versus-tumor effect provided by donor cells. Donor chimerism is utilized early after transplantation to evaluate engraftment and to monitor the persistence of donor hematopoiesis.
OBJECTIVE(S): Literature is conflicting regarding to the prognostic utility of early mixed …
Authors
Radford M; Garcia-Horton A; Badami R; Jin E; Usmani N; Grafodatskaya D; McCready E; Khalaf D; Walker I; Leber B
Journal
Transplantation and Cellular Therapy, Vol. 31, No. 2, pp. 77.e1–77.e20
Publisher
Elsevier
Publication Date
2 2025
DOI
10.1016/j.jtct.2024.11.006
ISSN
2666-6367